Cargando…
Liquid profiling of circulating tumor DNA in colorectal cancer: steps needed to achieve its full clinical value as standard care
The analysis of circulating tumor DNA (ctDNA) is at the threshold of implementation into standard care for colorectal cancer (CRC) patients. However, data about the clinical utility of liquid profiling (LP), its acceptance by clinicians, and its integration into clinical workflows in real‐world sett...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9120900/ https://www.ncbi.nlm.nih.gov/pubmed/34873826 http://dx.doi.org/10.1002/1878-0261.13156 |
_version_ | 1784711036513812480 |
---|---|
author | Hedtke, Maren Pessoa Rejas, Rodrigo Froelich, Matthias F. Ast, Volker Duda, Angelika Mirbach, Laura Costina, Victor Martens, Uwe M. Hofheinz, Ralf‐Dieter Neumaier, Michael Haselmann, Verena |
author_facet | Hedtke, Maren Pessoa Rejas, Rodrigo Froelich, Matthias F. Ast, Volker Duda, Angelika Mirbach, Laura Costina, Victor Martens, Uwe M. Hofheinz, Ralf‐Dieter Neumaier, Michael Haselmann, Verena |
author_sort | Hedtke, Maren |
collection | PubMed |
description | The analysis of circulating tumor DNA (ctDNA) is at the threshold of implementation into standard care for colorectal cancer (CRC) patients. However, data about the clinical utility of liquid profiling (LP), its acceptance by clinicians, and its integration into clinical workflows in real‐world settings remain limited. Here, LP tests requested as part of routine care since 2016 were retrospectively evaluated. Results show restrained request behavior that improved moderately over time, as well as reliable diagnostic performance comparable to translational studies, with an overall agreement of 91.7%. Extremely low ctDNA levels at < 0.1% in over 20% of cases, a high frequency of concomitant driver mutations (in up to 14% of cases), and ctDNA levels reflecting the clinical course of disease were revealed. However, certain limitations hampering successful translation of ctDNA into clinical practice were uncovered, including the lack of clinically relevant ctDNA thresholds, appropriate time points of LP requests, and integrative evaluation of ctDNA, imaging, and clinical findings. In conclusion, these results highlight the potential clinical value of LP for CRC patient management and demonstrate issues that need to be addressed for successful long‐term implementation in clinical workflows. |
format | Online Article Text |
id | pubmed-9120900 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-91209002022-05-21 Liquid profiling of circulating tumor DNA in colorectal cancer: steps needed to achieve its full clinical value as standard care Hedtke, Maren Pessoa Rejas, Rodrigo Froelich, Matthias F. Ast, Volker Duda, Angelika Mirbach, Laura Costina, Victor Martens, Uwe M. Hofheinz, Ralf‐Dieter Neumaier, Michael Haselmann, Verena Mol Oncol Research Articles The analysis of circulating tumor DNA (ctDNA) is at the threshold of implementation into standard care for colorectal cancer (CRC) patients. However, data about the clinical utility of liquid profiling (LP), its acceptance by clinicians, and its integration into clinical workflows in real‐world settings remain limited. Here, LP tests requested as part of routine care since 2016 were retrospectively evaluated. Results show restrained request behavior that improved moderately over time, as well as reliable diagnostic performance comparable to translational studies, with an overall agreement of 91.7%. Extremely low ctDNA levels at < 0.1% in over 20% of cases, a high frequency of concomitant driver mutations (in up to 14% of cases), and ctDNA levels reflecting the clinical course of disease were revealed. However, certain limitations hampering successful translation of ctDNA into clinical practice were uncovered, including the lack of clinically relevant ctDNA thresholds, appropriate time points of LP requests, and integrative evaluation of ctDNA, imaging, and clinical findings. In conclusion, these results highlight the potential clinical value of LP for CRC patient management and demonstrate issues that need to be addressed for successful long‐term implementation in clinical workflows. John Wiley and Sons Inc. 2021-12-20 2022-05 /pmc/articles/PMC9120900/ /pubmed/34873826 http://dx.doi.org/10.1002/1878-0261.13156 Text en © 2021 The Authors. Molecular Oncology published by John Wiley & Sons Ltd on behalf of Federation of European Biochemical Societies https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Articles Hedtke, Maren Pessoa Rejas, Rodrigo Froelich, Matthias F. Ast, Volker Duda, Angelika Mirbach, Laura Costina, Victor Martens, Uwe M. Hofheinz, Ralf‐Dieter Neumaier, Michael Haselmann, Verena Liquid profiling of circulating tumor DNA in colorectal cancer: steps needed to achieve its full clinical value as standard care |
title | Liquid profiling of circulating tumor DNA in colorectal cancer: steps needed to achieve its full clinical value as standard care |
title_full | Liquid profiling of circulating tumor DNA in colorectal cancer: steps needed to achieve its full clinical value as standard care |
title_fullStr | Liquid profiling of circulating tumor DNA in colorectal cancer: steps needed to achieve its full clinical value as standard care |
title_full_unstemmed | Liquid profiling of circulating tumor DNA in colorectal cancer: steps needed to achieve its full clinical value as standard care |
title_short | Liquid profiling of circulating tumor DNA in colorectal cancer: steps needed to achieve its full clinical value as standard care |
title_sort | liquid profiling of circulating tumor dna in colorectal cancer: steps needed to achieve its full clinical value as standard care |
topic | Research Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9120900/ https://www.ncbi.nlm.nih.gov/pubmed/34873826 http://dx.doi.org/10.1002/1878-0261.13156 |
work_keys_str_mv | AT hedtkemaren liquidprofilingofcirculatingtumordnaincolorectalcancerstepsneededtoachieveitsfullclinicalvalueasstandardcare AT pessoarejasrodrigo liquidprofilingofcirculatingtumordnaincolorectalcancerstepsneededtoachieveitsfullclinicalvalueasstandardcare AT froelichmatthiasf liquidprofilingofcirculatingtumordnaincolorectalcancerstepsneededtoachieveitsfullclinicalvalueasstandardcare AT astvolker liquidprofilingofcirculatingtumordnaincolorectalcancerstepsneededtoachieveitsfullclinicalvalueasstandardcare AT dudaangelika liquidprofilingofcirculatingtumordnaincolorectalcancerstepsneededtoachieveitsfullclinicalvalueasstandardcare AT mirbachlaura liquidprofilingofcirculatingtumordnaincolorectalcancerstepsneededtoachieveitsfullclinicalvalueasstandardcare AT costinavictor liquidprofilingofcirculatingtumordnaincolorectalcancerstepsneededtoachieveitsfullclinicalvalueasstandardcare AT martensuwem liquidprofilingofcirculatingtumordnaincolorectalcancerstepsneededtoachieveitsfullclinicalvalueasstandardcare AT hofheinzralfdieter liquidprofilingofcirculatingtumordnaincolorectalcancerstepsneededtoachieveitsfullclinicalvalueasstandardcare AT neumaiermichael liquidprofilingofcirculatingtumordnaincolorectalcancerstepsneededtoachieveitsfullclinicalvalueasstandardcare AT haselmannverena liquidprofilingofcirculatingtumordnaincolorectalcancerstepsneededtoachieveitsfullclinicalvalueasstandardcare |